Antibody-Nkg2d Ligand (Rae-1Beta) Fusion Protein for Breast Cancer Therapy

doi 10.21236/ada446435
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Defense Technical Information Center

Related search

Delivery of NKG2D Ligand Using an Anti-Her2 Antibody-Nkg2d Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response

Cancer Research
Cancer ResearchOncology
2010English

Breast Cancer Therapy Using Antibody-Endostatin Fusion Proteins

2008English

NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy

Frontiers in Immunology
AllergyImmunology
2018English

Chronic in Vivo Interaction of Dendritic Cells Expressing the Ligand Rae-1ε With NK Cells Impacts NKG2D Expression and Function

ImmunoHorizons
2017English

Cancer Gene Therapy via NKG2D and FAS Pathways

2011English

VEGFR2 Targeted Antibody Fused With MICA Stimulates NKG2D Mediated Immunosurveillance and Exhibits Potent Anti-Tumor Activity Against Breast Cancer

Oncotarget
Oncology
2016English

Breast Cancer: Rank Ligand Inhibition

Breast Care
SurgeryOncology
2010English

Characterization of a Re-Engineered, Mesothelin-targetedPseudomonasexotoxin Fusion Protein for Lung Cancer Therapy

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

A Novel Bispecific Antibody Against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy